Introduction
The new ESC guidelines [1] have provided updated evidencebased recommendations for the clinical diagnosis of heart failure. Box 1 summarises the diagnostic process in the case of a patient presenting with acute dyspnoea and suspected acute heart failure. Table 1 summarises the diagnostic elements that should be assessed in a patient with non-acute onset, as described below. The diagnostic process is illustrated in an algorithm developed by the ESC with an adaption shown in Figure 1 . [1] 
Initial assessment
In patients with non-acute onset, presenting with symptoms or signs of heart failure non-urgently in primary care or in a hospital outpatient clinic, the probability of heart failure should first be evaluated by assessing history and symptomatology and with physical examination (Table 1) . During these steps, at least one element should be abnormal to continue to consider a diagnostic hypothesis of heart failure ( Figure 1 ). If so, plasma natriuretic peptides (NPs) should be measured. This measurement will allow informed decision-making as to whether the patient needs to undergo an echocardiogram (see paragraph below). If no abnormalities are found, heart failure is unlikely and other diagnoses should be considered. Echocardiography is also a first-step option, e.g. if more available or if it is deemed that the diagnostic yield would be higher.
Thus clinical diagnosis of heart failure is based on the clinical assessment of patient's prior clinical history and reported symptoms combined with the observation of signs derived from a thorough physical examination and selected laboratory and imaging tests. Establishing the subtype of heart failure (HFpEF, HFrEF, HFmrEF), further requires the application of ESC criteria described in Definition and Classification of Heart Failure.
History
It is crucial to obtain a detailed history to ascertain the presence or absence of possible causes of cardiac damage. [2] Heart failure is much less likely in the absence of a relevant medical history suggesting an increased risk of cardiac damage, compared to the patient with significant risk factors such as previous myocardial infarction. [2] [3] In advanced economies nearly 60% of patients diagnosed with acute heart failure have underlying coronary artery disease [4] and, in patients with acute coronary syndromes, myocardial ischemia is often a precipitant factor, especially for de novo acute heart failure. [5] Thus details derived from an accurate clinical history should be taken into account especially known risk factors for the development of heart failure. A prior diagnosis of heart failure, diabetes, hypertension, valvular heart disease, advanced age, male sex, and obesity have all been found to predict the fluid or volume overload typical of congestive heart failure. [6, 7] For these reasons, the first diagnostic step is to assess the probability of heart failure and this consists of the evaluation of a potential history of coronary artery disease, arterial hypertension, diuretic use, orthopnoea/paroxysmal nocturnal dyspnea, and other conditions ( Table 1) . Knowledge of the precipitating causes may also have therapeutic and prognostic implications.
Clinical evaluation of symptoms and signs
As described in Definition and Classification of Heart Failure, heart failure is characterised by dyspnoea, fatigue and signs of volume overload, which may include peripheral edema and pulmonary rales. These symptoms and signs are often the consequence of systemic and pulmonary congestion, due to high left ventricular filling pressures. Even in the absence of overt clinical congestion (with elevation of left ventricular end-diastolic pressure), haemodynamic congestion may also occur, sometimes preceding overt clinical congestion. [4] Notably, while the severity of many other symptoms need not necessarily implicate a poor prognosis [4] ,patients with clinical or haemodynamic congestion have worse mortality and rehospitalisation rates. [8] [9] [10] Several tools may be used for the assessment of pulmonary congestion. In clinical practice, the use of cardiac catheterization -the gold standard for the assessment of left-side congestion -is hindered by its invasive nature, and less invasive measures are therefore preferred. Among these, physical examination, body weight, serum sodium, natriuretic peptides and chest X-ray are useful tools for the diagnosis. Beyond the identification of signs of congestion, the evaluation of volume status and peripheral perfusion is pivotal for the diagnosis of heart failure, especially in the acute setting. [1] Given that heart failure is classically characterised by low cardiac output and high filling pressures, an objective measure of volume status is a useful indicators as to the likelihood of the diagnosis. [7] An accurate estimation of volume status is especially critical in the early management of acute heart failure patients. [7] However, assessing volume overload is challenging for the clinician. Errors at this stage often lead to an inappropriate therapy plan and may even increase the risk of mortality. [11] Beyond the baseline evaluation, volume status and peripheral perfusion must be monitored over time. Follow-up assessments of all these parameters will give important warnings on the patient response to treatment, possibly providing the background for modifying treatment. [1] Some symptoms of heart failure such as peripheral oedema, dyspnoea on exertion and fatigue may not be so helpful for the clinician in making a differential diagnosis, as they are relatively non-specific. [12, 3, 5] Orthopnoea and paroxysmal nocturnal dyspnoea are more typical of heart failure, but are less common and, therefore, less sensitive. [7] Signs such as an audible third heart sound (S3), displacement of the apical impulse and elevated jugular venous pressure are specific for heart failure, but their identification is more difficult [4] and reproducibility is poor. [5, 13] Also signs of fluid retention may disappear soon after diuretic therapy. [1] Finally, in some groups such as the obese, the elderly and chronic lung disease patients, the identification of symptoms and signs is even more difficult. [14] [15] [16] Notably, comorbidities may further complicate the diagnosis. In these cases, rapid objective measures of volume status are needed. [7] 
Physical examination
In a case of suspected heart failure, physical examination should consist of the following elements: observation of the patient, palpation and auscultation of the heart, examination of vital signs, heart and lungs as well as neck veins. [8, 9, 5, 4] Additional physical examination may include evaluation of the abdomen and extremities. [2] In particular, jugular venous distention, the presence of rales, and lower extremity oedema are evaluated. [7] The presence of pulmonary rales, jugular venous distention, hepatojugular reflux and pitting peripheral oedema is suggestive of volume overload and therefore increases the likelihood of a diagnosis of heart failure. [17, 4] On the other hand it should be noted that the diagnosis of heart failure is not necessarily ruled out if these indicators are not present. [4] 
Laboratory assessment
Laboratory testing is recommended by the ESC guidelines as part of the routine diagnostic process in the case of suspected heart failure. Such laboratory investigations can also direct the clinician to explore alternative diagnoses and highlight potentially modifiable causes of heart failure. [4, 5] As aforementioned, plasma NPs should be measured after the first diagnostic steps shown in Table 1 and Figure 1 . According to the ESC guidelines, the measurement of NPs should be used to rule out heart failure, and not to establish the diagnosis. Other laboratory exams that should be performed primarily to rule out heart failure are listed in Table 1 .
Cardiac imaging
The role of cardiac imaging for the diagnosis of heart failure has been well-established. In fact, documentation of an underlying cardiac cause is fundamental to diagnose heart failure. The gold standard for heart failure diagnosis, among the cardiac imaging tools, is echocardiography. This is due to its accuracy, safety, cost-effectiveness and availability. [1] 
Echocardiography
Beyond myocardial abnormality, other impairments leading to heart failure may be documented by echocardiography (Table   1 ). For instance, it allows the assessments of chamber volumes, ventricular systolic and diastolic function, wall thickness, valve function, and pulmonary hypertension. Knowledge of these characteristics and of the underlying cardiac problem will also put the background for the treatment plan. In non-acute patients, echocardiography is recommended after the patient is identified as eligible by NP measurement (if the NP level is above the exclusion threshold) or if NP measurement is not available. [1] An early echocardiographic examination is recommended for patients with de novo acute heart failure or unknown cardiac function. In high-risk patient groups echocardiography must be performed immediately: patients with haemodynamic instability (particularly in cardiogenic shock) and those suspected of acute life-threatening structural or functional cardiac abnormalities. [1] Echo can be crucial in acute HF, for immediate recognition of treatment options based on clinical phenotypes of AHF.
Other diagnostic tools
A 12-lead electrocardiogram is recommended "in order to determine heart rhythm, heart rate, QRS morphology and QRS duration, and to detect other relevant abnormalities". [1] Electrocardiography will provide additional information for both the diagnosis and the aetiology (e.g. myocardial infarction) and treatment of heart failure. Indeed, heart failure is rarely associated with a totally normal electrocardiogram. [1] Unfortunately, it has been demonstrated that the electrocardiogram has low specificity. [17] [18] 5 ] Therefore, it may be used more to exclude a diagnosis of heart failure rather than to establish one.
Chest X-ray, exercise testing, invasive haemodynamic assessments and endomyocardial biopsy are additional tests that may be used in the diagnostic process. [1, 2] Lung ultrasound is emerging as a useful test in selected patients for the accurate assessment of pulmonary congestion. [20] Finally, the role of biomarkers for clinical diagnosis of heart failure is under debate. On the one hand, no clear evidence has been collected to recommend their use in heart failure diagnosis. [1] On the other hand, there are preliminary, encouraging data suggesting their promising use as additional tools in monitoring the progress of clinical cases of heart failure and in the identification of the likely aetiology.
Declarations of Interest
The authors declare no conflicts of interest. Figure 1 . Algorithm for the diagnosis of heart failure in non-acute setting. HF = heart failure; NPs = plasma natriuretic peptides *not suitable for patients taking angiotensin receptor neprilysin inhibitors ** normal ventricular and atrial volumes and function ***consider other causes of elevated natriuretic peptides
